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Abstract
Uveal melanoma (UM) is a rare aggressive intraocular tumour with a propensity for liver metastases, occurring in
50% of patients. The tumour suppressor BAP1 is considered to be key in UM progression. Herein, we present
the largest study to date investigating cellular expression patterns of BAP1 protein in 165 UMs, correlating these
patterns to prognosis. Full clinical, histological, genetic, and follow-up data were available for all patients. BAP1
gene sequencing was performed on a subset of 26 cases. An independent cohort of 14 UMs was examined for
comparison. Loss of nuclear BAP1 (nBAP1) protein expression was observed in 54% (88/165) UMs. nBAP1
expression proved to be a significant independent prognostic parameter: it identified two subgroups within
monosomy 3 (M3) UM, which are known to have a high risk of metastasis. Strikingly, nBAP1-positiveM3 UMs
were associated with prolonged survival compared to nBAP1-negative M3 UMs (Log rank, p5 0.014). nBAP1 pro-
tein loss did not correlate with a BAP1 mutation in 23% (6/26) of the UMs analysed. Cytoplasmic BAP1 protein
(cBAP1) expression was also observed in UM: although appearing ‘predominantly diffuse’ in most nBAP1-negative
UM, a distinct ‘focal perinuclear’ expression pattern – localized immediately adjacent to the cis Golgi – was seen
in 31% (18/59). These tumours tended to carry loss-of-function BAP1 mutations. Our study demonstrates loss of
nBAP1 expression to be the strongest prognostic marker in UM, confirming its importance in UM progression.
Our data suggest that non-genetic mechanisms account for nBAP1 loss in a small number of UMs. In addition,
we describe a subset of nBAP1-negative UM, in which BAP1 is sequestered in perinuclear bodies, most likely
within Golgi, warranting further mechanistic investigation.
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Introduction
The incidence of uveal melanoma (UM) varies
between 3 and 8 per million per year in Caucasians,
making it the most common primary intraocular
malignancy in adults [1,2]. Whilst primary tumours
are successfully treated using either surgery and/or
radiotherapy [3], up to 50% of patients die from met-
astatic disease, typically occurring in the liver, for
which there is currently no effective systemic therapy
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[4,5]. Stratifying UM patients as at either high or low
risk of metastatic spread is critical to ensure patients
are managed accordingly: low metastatic risk UM
patients can be reassured that they are very unlikely
to develop metastases, whilst high metastatic risk
UM patients can undergo more intensive liver screen-
ing, with the potential of undergoing liver resection
surgery at the earliest onset of relapse, and/or enrol-
ment in clinical trials [6]. Prognostication involves
the integration of clinical, histological, and genetic
features of the tumour, in order to obtain a refined
predicted risk [6,7].
UM is characterized by distinct gross chromosomal
abnormalities that are associated with patient out-
come, the most common being monosomy 3 (M3),
which corresponds with a significantly worse progno-
sis [8–12]. M3 is frequently accompanied by polys-
omy 8q, and increasing copies of 8q significantly
correlate with reduced survival, in a dose-dependent
fashion [8,10,13,14]. Further abnormalities described
in UM include loss of 1p, which is associated with
poor prognosis in the context of M3 [15], and gains
on 6p, which, in the absence of additional chromo-
somal abnormalities, correspond with a good progno-
sis [16,17]. More recently, mutations occurring in
UM have been identified in several genes, including
GNAQ, GNA11, BAP1, SF3B1, EIF1AX, PLCB4, and
CYSLTR2 [11,18–22]. In particular, inactivating
BAP1 mutations are associated with a poor outcome,
being present in 84% of all UMs that went on to
produce metastases [19,23,24]. BAP1 mutations simi-
larly correspond with a significantly worse prognosis
in renal clear cell carcinoma [25] and cholangiocarci-
noma [26], whilst in mesothelioma BAP1 inactivation
is associated with a good prognosis [27]. Families
with members carrying germline mutations in BAP1
have also been described, with individuals most often
affected by mesothelioma, melanomas including UM,
and renal cell carcinoma [28,29].
BRCA1-associated protein 1 (BAP1), encoded by
BAP1 on chromosome 3p21.1, is a nuclear-localized
deubiquitylase (DUB) belonging to the ubiquitin
carboxy-terminal hydrolase family of DUBs [19,30].
The 729-amino acid BAP1 protein includes an
N-terminal catalytic domain, a bipartite C-terminal
nuclear localisation signal (NLS), and binding domains
for BRCA1 (Breast Cancer 1), BARD1 (BRCA1-asso-
ciated RING domain protein 1), and HCF1 (Host cell
factor 1), among others [30–32]. BAP1 has multiple
functions, including involvement in DNA damage
responses [33–35], transcriptional activation [35],
chromatin remodelling [36], and cell cycle regulation
[33,37].
Functionally, BAP1 nonsense or frameshift muta-
tions lead to truncated BAP1 protein with loss of
nuclear localisation and/or reduced protein or mRNA
stability [23]. This has led to several recent studies
assessing the prevalence of nuclear BAP1 protein
expression (nBAP1) in UM, and correlating this with
clinical outcome [23,38,39]. Koopmans et al [39] and
Kalirai et al [38] observed loss of nBAP1 protein
expression in 43% and 51% of all UM, respectively,
which was significantly associated with increased met-
astatic risk, along with other clinical features linked to
poor prognosis. In the latter study, we also noted the
presence of differing cytoplasmic staining patterns of
BAP1 protein (cBAP1) using immunohistochemistry
(IHC). This has also been observed by groups examin-
ing BAP1 IHC expression in other cancers [40–42],
and in atypical Spitz tumours [43]. Although the sig-
nificance of cBAP1 remains unclear, shuttling of
BAP1 between the cytoplasm and nucleus has been
previously described [44]. Indeed, in cell lines derived
from mesothelioma patients, mutant BAP1 was associ-
ated with cytoplasmic sequestration of the protein due
to loss of the NLS [45].
Herein, we report the largest study to date of BAP1
protein expression in UM and provide a comprehen-
sive analysis of nBAP1 and cBAP1, correlating these
findings with clinical, genetic, and histopathological
tumour characteristics, as well as with outcome.
Materials and methods
Ethics
This study conformed to the principles of the Decla-
ration of Helsinki and Good Clinical Practice guide-
lines. Approval for the study was obtained from the
Health Research Authority (NRES REC ref 16/SW/
0112), and all patients provided informed consent.
Validation studies were carried out on an inde-
pendent set of samples obtained from The Ohio State
University (OSU) and collected according to a sepa-
rate IRB (OSU2006C0045).
Sample collection
For samples collected in Liverpool, 4 mm sections
were cut from formalin-fixed paraffin-embedded
(FFPE) material obtained from 145 UM patients who
were treated by enucleation or local resection at the
Liverpool Ocular Oncology Centre (LOOC), Royal
Liverpool University Hospital NHS Trust between
January 2013 and December 2015. For a further 20
patients, BAP1 IHC had already been undertaken as
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part of their routine prognostication, and nBAP1
expression data were available from the Ocular Oncol-
ogy Biobank.
Fourteen samples from OSU were provided as 4
mm sections cut from FFPE blocks.
Immunohistochemistry
The IHC for BAP1was performed as previously
described [38] using the Dako PT Link and the Dako
EnVision Flex kit on the Autostainer Plus according
to the manufacturer’s standard instructions (Dako,
Agilent Technologies LDA UK Limited, Stockport,
UK). Briefly, a mouse anti-human BAP1 antibody
(0.5 lg ml21; C-4, Santa Cruz, Insight Biotechnology
Ltd, Middlesex, UK) and a rabbit anti-human GM130
antibody (0.236 lg ml21; EP892Y, Abcam, Cam-
bridgeshire, UK; a marker for the Golgi apparatus)
were used. Bound antibody was visualized with
either EnVisionTM FLEX 3,30-diaminobenzidine
(DAB1) (Dako) or aminoethylcarbazole (AEC; for
highly pigmented tumours) (Vector Labs UK, Peter-
borough, UK). All sections were counterstained with
Mayer’s haematoxylin (VWR International Ltd, Lut-
terworth, UK), blued with Scott’s tap water (Leica
Microsystems Ltd, Milton Keynes, UK) and mounted
with either AquatexTM (VWR) or DPX mountant for
AEC or DAB1 sections, respectively. Human pan-
creas tissue was used as a positive control for both
BAP1 and GM130. Mouse IgG1 was used as a nega-
tive control for BAP1 in tissue sections.
Scoring
The IHC stained slides were scored by four inde-
pendent investigators (SEC, HK, NF, ST) using a
light microscope (Nikon Eclipse E600). A binary
score was used for nBAP1expression; with cases
being defined as positive when staining was present
in tumour cell nuclei, and negative in its absence.
cBAP1 was also defined as ‘positive’ or ‘negative’,
with the subcellular localisation additionally being
recorded as either ‘predominantly diffuse’, or ‘pre-
dominantly focal perinuclear’.
DNA extraction and quantification
All methods for DNA extraction from FFPE and fro-
zen UM samples and their quantification have been
previously described elsewhere [46,47].
Chromosomal copy number analysis
The Multiplex Ligation Dependent Probe Amplifica-
tion (MLPA) and microsatellite (MSA) procedures
for the assessment of chromosome 3 copy number
alterations were performed as previously described
[8,48,49]. MLPA was performed in all cases
yielding> 100 ng DNA whilst MSA was undertaken
for samples with lower DNA yield. For samples
obtained from OSU, chromosome 3 status was
assessed by microsatellite-based genotyping [46].
Mutation analysis
We hypothesized that the phenomenon of ‘focal peri-
nuclear’ cBAP1 may be due to distinct BAP1 muta-
tions resulting in mis-localisation. To study this, we
sequenced all BAP1 exons in 9 UM cases that were
nBAP1 positive as well as 17 nBAP1 negative UM
(7 cBAP1 diffuse, 9 cBAP1 focal perinuclear, and 1
cBAP1 negative). These cases were chosen because
they demonstrated a clear immunophenotype for
nBAP1 and also provided good quality DNA. Tar-
geted sequencing of BAP1 in these cases was per-
formed by the Rotterdam Ocular Melanoma Study
group, using the Ion Torrent Personal Genome
Machine or by direct Sanger sequencing at OSU
[50]. SNPs were called using Torrent Suite Software
V4.4.3 (Thermofisher Scientific Ltd, Hemel Hemp-
stead, UK) and variants were identified and annotated
using SnpEff version 3.2a.
A second cohort of 14 UM samples had previously
undergone direct sequencing for BAP1 alterations at
OSU. Results were read by aligning with the refer-
ence sequence provided by Genbank accession num-
ber NM_004656.2, utilizing the Sequencher software
(Version 4.8, Gene Codes Corp, Ann Arbor, MI,
USA).
Statistical analysis
Multivariate analysis of risk factors associated with
development of metastatic disease was undertaken
using the Cox proportional hazards model for all
covariates with p 0.10 by univariate analysis. Sur-
vival time (months) was calculated from the date of
first diagnosis until death, or study closure on 28
February 2017. All analyses were carried out using
SPSS Statistics v.24 (IBM).
Results
Patient demographics and tumour sample details
Initial analyses relate to 165 UM patients treated
with surgical excision at the LOOC between January
2013 and December 2015 (supplementary material,
Table S1); 154 enucleation, 9 local resection and 2
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endoresections. In 29 cases, the surgical excision ana-
lysed was not the primary treatment, but instead was
performed when tumour recurrence or local compli-
cations had followed first treatment. The median
time from first presentation to surgical excision for
these cases was 33.5 months (range 1–570).
Of the 165 patients, 96 were males and 69 females,
with a median age of 63 years at primary manage-
ment (range, 20–88 years) and a median follow-up of
31.3 months (range, 5.7–348.5 months). At the time
of study closure (28 February 2017), 133/165 (81%)
UM patients were alive; 25/165 (15%) patients had
died from metastatic disease, and 7/165 (4%) had
died from other causes. The median largest basal
diameter (LBD) was 14.4 mm (range, 3.3–23.6 mm),
with a median tumour height of 8.3 mm (range, 0.1–
18.5 mm). Epithelioid cells were present in 104/165
(63%) UM, 61/165 (37%) tumours involved the cili-
ary body, and 20/165 (12%) had extraocular exten-
sion. Further histomorphological characteristics of the
tumours are summarized in supplementary material,
Table S1.
As determined by either MLPA (153 cases) or
MSA (12 cases), 103/165 (62%) UM were classified
as M3, 48/165 (29%) UM as disomy 3 (D3), and one
UM(1%) was isodisomy 3; in all subsequent statisti-
cal analyses, this was classified with the M3 cases
(supplementary material, Table S2). Thirteen UM
(8%) could not be classified as either M3 or D3 due
to poor quality DNA.
Nuclear BAP1 protein localisation was observed in
77/165 (45.5%) UM, and absent in 88/165 (54.5%)
(Figure 1 and supplementary material, Tables S1 and
S2). There was no significant heterogeneity of
nBAP1 protein expression amongst the tumour cells,
such that the cases were either clearly nBAP1 posi-
tive or negative. Glial cells within the optic nerve as
well as within the plexiform cells of the neurological
retina were used as intrinsic positive controls for
nBAP1 expression (Figure 1A). Pancreas sections
served as external controls (Figure 1B). Non-
neoplastic uveal melanocytes were positive for
nBAP1 expression (Figure 1C). No positive staining
was observed in sections incubated with mouse IgG1
instead of the BAP1 antibody.
As expected, the majority of M3 (84/104, 81%)
were nBAP1 negative; however, 20/104 (19%) dem-
onstrated nBAP1positivity (Figure 2A). Of the 48 D3
UM, the majority (46/48, 96%) were nBAP1 positive.
Two D3 UM were nBAP1 negative and were subse-
quently re-tested by MSA to rule out isodisomy 3,
which is not detectable by MLPA; both had a D3
classification by MSA. Of interest, 90 UM demon-
strated 8q gains with 61/90 (68%) being BAP1
negative (supplementary material, Table S2). Further-
more, of the 25 UM patients who died from meta-
static UM, 22 (88%) had nBAP1 negative primary
tumours (supplementary material, Table S1). Of the
three nBAP1 positive cases in this group, the chro-
mosome 3 status was M3 in one, D3 in one, and
unclassifiable in the remaining case.
Survival
Kaplan-Meier survival curves and tables were exam-
ined for all primary UMs stratified according to
nBAP1 protein expression or chromosome 3 status.
Both UMs negative for nBAP1 (Log Rank, p< 0.001)
and M3 UMs (Log rank, p5 0.001) were significantly
associated with a reduced survival time (Figure 1D,E).
The cases were further subdivided according to their
chromosome 3 status (Figure 2A–C). Strikingly, M3/
nBAP1 positive UM had a significantly better progno-
sis than M3/nBAP1 negative tumours (Log rank,
p5 0.014), which was in fact similar to that of
patients with D3/nBAP1 positive UM (Figure 2B).
Univariate and multivariate analysis
Univariate analysis identified the following factors as
significantly associated with survival time (supple-
mentary material, Table S3): nBAP1 protein expres-
sion, p 0.001 (HR 0.173; 95% CI 0.067–0.450);
age at primary management, p5 0.005 (HR 1.046;
95% CI 1.014–1.080); presence of closed connective
loops, p5 0.003 (HR 3.596; 95% CI 1.541–8.389);
mitotic count per 40 high power field, p5 0.016 (HR
1.029; 95% CI 1.005–1.054); epithelioid cell mor-
phology, p5 0.014 (HR 3.059; 95% CI 1.257–7.443);
tumour height, p5 0.002 (HR 1.169; 95% CI 1.058–
1.292); LBD, p5 0.006 (HR 1.142; 95% CI 1.039–
1.255); and chromosome 3 loss, p5 0.036 (HR
0.482; 95% CI 0.243–0.955). Multivariate analysis
demonstrated only nBAP1 protein expression as an
independent factor significantly associated with sur-
vival, p5 0.002 (HR 0.211; 95% CI 0.079–0.562) in
this cohort (Table 1).
Cytoplasmic BAP1 protein expression
We next examined the 145 UM stained by the Liver-
pool Ocular Oncology Research Group for cytoplas-
mic expression of BAP1. Eighteen of these were
excluded from the analysis due to high levels of pig-
mentation, which made the cBAP1 localisation diffi-
cult to distinguish, so 127 UM were ultimately
included in the analysis. cBAP1 staining was not
observed in the glial cells of the optic nerve or the
plexiform cells of the neurological retina, which
4 N Farquhar et al
VC 2017 The Authors The Journal of Pathology: Clinical Research published by
The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd
J Path: Clin Res 2017
Figure 1. Prognostic value of nuclear BAP1 protein expression. (A–C) Representative images of nuclear BAP1 protein (nBAP1) expres-
sion in primary UM (x10 magnification); insets show nBAP1 at x40 magnification. (A) nBAP1 negative tumour with focal perinuclear
cBAP1. Intrinsic nuclear positivity is present in the adjacent neural retinal tissue (bottom inset). (B) Positive (left) and negative (right)
nBAP1 staining in pancreas control sections. (C) nBAP1 staining in non-neoplastic uveal melanocytes. (D) nBAP1 positive UM (left)
and a nBAP1 negative UM (right). (E, F) Kaplan-Meier survival curves and tables for primary UM in the Liverpool cohort stratified
according to: (E) nBAP1 protein expression (n5 165; Log Rank, p< 0.001) (nBAP1 protein expression was scored as positive or nega-
tive); or (F) chromosome 3 status (n5 152; Log Rank, p5 0.001), where only cases with a discernible normal or loss of chromosome
3 were included. Number of events indicates the number of deaths due to metastatic melanoma. Log-rank tests were used to com-
pare survival across groups. BAP1 positivity was detected using a brown chromogen in (A), (B), and (D) and a red chromogen in (C).
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served as intrinsic positive controls, nor was it
detected in mouse IgG1 incubated negative control
sections. cBAP1 localisation was recorded as ‘predom-
inantly diffuse’, ‘predominantly focal perinuclear’, or
negative. Of the127 UM examined, 68 (53.5%) were
nBAP1 positive, whilst 59 (46.5%) were nBAP1 nega-
tive (Figure 3). nBAP1 positive UM demonstrated
‘predominantly diffuse’ cytoplasmic staining in 53/68
(77.9%) cases examined; the remaining 15/68 (22.1%)
showed no detectable cBAP1 expression, with none
showing the focal perinuclear phenotype.
Of particular interest were the nBAP1 negative
UMs that exhibited a distinct ‘focal perinuclear’
cBAP1 localisation in 18/59 (31%) cases (Figure
3A,B). ‘Predominantly diffuse’ cBAP1 was noted in
36/59 (61%) cases and there was no detectable
cBAP1 in 5/59 (8%). Overall, these results suggest
that complete loss of BAP1protein expression is
uncommon in UM.
This ‘focal perinuclear’ cBAP1 phenotype did not
significantly affect overall survival relative to pre-
dominantly diffuse or negative cBAP1 in the nBAP1
negative UM (Log rank, p5 0.925; Figure 3C), nor
did it correlate significantly with other clinical
parameters or gross chromosomal abnormalities.
To take into account possible artefacts created by
fixation and processing, we further examined our
cBAP1 findings using an external independent cohort
of UM (n5 14) with available BAP1 mutational status
from the pathology archives of OSU. In keeping with
the frequency of nBAP1 loss by IHC in the Liverpool
cohort, 7/16 (44%) UM were nBAP1 positive and 9/
16 (56%) were nBAP1 negative. All nBAP1 positive
UM in this cohort had ‘predominantly diffuse’
cBAP1. nBAP1 negative UM showed ‘focal perinu-
clear’ cBAP1 localisation in 3/9 (33%) cases with6/9
(66%) showing ‘predominantly diffuse’ cBAP1 stain-
ing, again consistent with our findings above.
Golgi localisation of cytoplasmic BAP1
Our results showing “focal perinuclear” cBAP1 pro-
tein accumulation in nBAP1 negative (but not nBAP1
Figure 2. nBAP1 status contributes additional prognostic information in M3-UM patients. (A) Pie chart summarizing the breakdown
of nBAP1 staining and chromosome 3 status in the Liverpool cohort of patients, n5 165. (B, C) Kaplan-Meier survival curves and
tables estimating disease-free survival in UM patients stratified by: (B) nBAP11ve/–ve status in monosomy 3 (M3) patients, n5 104
and (C) nBAP11ve/–ve status in disomy 3 (D3) patients, n5 48. Number of events indicates the number of deaths due to metastatic
melanoma. Log-rank tests were used to compare survival across groups.
Table 1. Multivariate analysis of risk factors associated with
metastasis in uveal melanoma
Variable Significance
Hazard
ratio (HR)
95% CI for HR
Lower Upper
nBAP1 0.006 0.212 0.070 0.645
AgePM 0.071 1.030 0.997 1.064
Chr3 0.974 1.011 0.540 1.892
AgePM, age at primary management; Chr3, Chromosome 3; nBAP1, nuclear
BAP1; CI, confidence interval.
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positive) UM suggests that this reflects aberrant BAP1
processing and/or trafficking. We noted that the peri-
nuclear distribution was similar to the location of the
Golgi apparatus: to assess whether the cBAP1 may
indeed be accumulating in the Golgi apparatus,
adjacent serial UM sections were stained for BAP1
and the cis Golgi marker, GM130. Interestingly, the
GM130 and cBAP1 staining profiles were very simi-
lar, indicating that BAP1 is localized near, or possibly
within, the cis Golgi in these cells (Figure 3D).
Figure 3. Cytoplasmic BAP1 exhibits differential localisation in UM. (A) Images showing either diffuse (left; DAB) or focal perinuclear
(centre; DAB and right; AEC) localisation of cytoplasmic BAP1 (cBAP1) in three nBAP1 negative UM (main image and insets are at
310 and 340 magnification, respectively; scale bars 200 lm). (B) Pie charts summarizing the breakdown of nBAP1 expression in the
127 UMs studied (left) and cBAP1 expression in the 59 nBAP1 negative cases (right). (C) Kaplan-Meier survival curve for 54 nBAP1
negative UM patients stratified by focal perinuclear and diffuse cBAP1 staining patterns. The difference in survival was not significant
(Log rank; p5 0.925). (D) Images showing similar localisation of focal perinuclear cBAP1 with the cis Golgi marker GM130 in 3 lm
serial sections of two UM cases (I and II) (scale bars 60 lm).
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BAP1 mutation analysis
As expected, all 9 nBAP1 positive UM had wild-type
BAP1. Of the 17 nBAP1 negative cases examined,
3/7 cBAP1 diffuse UM were wild-type for BAP1and
1/7 harboured a splice acceptor mutation prior to
exon 2, causing loss-of-function, while 3/7 had trun-
cating, loss-of-function BAP1 mutations (Figure 4
and supplementary material, Table S4). In contrast,
7/9 cBAP1 ‘focal perinuclear’ UM harboured loss-
of-function BAP1 mutations. In one case, exon 17
was flanked by an intron variant and a 30 UTR vari-
ant, the pathogenic significance of which is unclear.
The remaining case was wild-type for BAP1. In the
independent OSU cohort, 6/9 nBAP1 negative UM
harboured a BAP1 mutation, and 1/9 had a benign
variant rs149499021. In the nBAP1 positive UM,
4/5 showed no mutation with only one case having
the benign variant rs149499021 [40]. Of the three
cases showing ‘focal perinuclear’ cBAP1, two had
INDELs and one had a benign variant (supplementary
material, Table S5).
Overall, we identified 6/25 (24%) cases in both
cohorts analysed that were nBAP1 negative but did
not harbour a BAP1 mutation.
Figure 4. UMs with focal perinuclear cBAP1 tend to harbour loss-of-function BAP1 mutations. (A) Schematic showing the location of
mutations within the BAP1 gene. 50 and 30 UTRs are depicted in red. One UM had two mutations flanking exon 17 (1); (B) location
of the mutations shown in (A) mapped to the BAP1 protein (UCH, ubiquitin carboxy-terminal hydrolase domain; BARD1, BARD1-
binding domain; HBM, HCF1-binding domain; BRCA1, BRCA1-binding domain; ULD, UCH-37-like domain; NLS, nuclear localisation
signal. The location of cysteine, histidine, and aspartic acid residues of the catalytic triad are shown in the catalytic domain. (C) His-
togram showing the distribution of mutation types for the nBAP1 positive, nBAP1 negative (cBAP1 diffuse), nBAP1 negative (cBAP1
focal perinuclear), and nBAP1 negative (cBAP1 negative) UMs.
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Discussion
This is the largest study to date examining BAP1
protein expression in UM by IHC. Where feasible,
we have also correlated the nuclear and cytoplasmic
staining patterns of BAP1with clinical features,
including outcome, as well as with BAP1 sequencing
data. In this study, we have demonstrated that
nBAP1 protein expression is lost in 54% of UM, and
that nBAP1 is a significant independent prognostic
indicator, which identifies a subset of M3 UM with
nBAP1 expression that have prolonged survival as
compared with M3 UM that have lost nBAP1 expres-
sion. We provide evidence to suggest that the subcel-
lular localisation of cBAP1 in nBAP1-negative UM
is associated with the presence of BAP1 mutations.
That is, UM with ‘focal perinuclear’ cBAP1 tended
to carry loss-of-function BAP1 mutations compared
to UM with diffuse cytoplasmic BAP1.
Nuclear BAP1 findings
BAP1 IHC is currently routinely performed only on
surgically resected specimens in our centre. In the
current study, this included tumours resected because
of size, location, recurrence, secondary complica-
tions, and patient preference. Whilst we recognize
that there may be a potential bias as compared with
an analysis of all UM, the frequency of nBAP1 nega-
tivity in this study (54%) is consistent with that
reported in the literature (43–58%) [23,38,39]. Simi-
lar to these other reports, we demonstrated a correla-
tion between loss of nBAP1 expression and poor
prognostic parameters known to be associated with
‘high risk’ UM – i.e. increasing age at primary man-
agement; ciliary body involvement; increasing
tumour LBD; large tumour height; epithelioid cell
morphology; PAS-positive connective tissue loops;
and loss of chromosome 3 [6].
Previous studies have indicated that there is a
strong association between the absence of nBAP1
protein expression and mutations in BAP1 [23,39].
For example, Van de Nes et al demonstrated in a
cohort of 66 UM that 33/37 (89%) M3 UM had a
BAP1 mutation together with an absence of nBAP1
protein expression [23]. A similar proportion was
reported by Koopmans et al in their study of 74 UM,
with 88% of the M3 UM harbouring a BAP1 muta-
tion together with loss of nuclear protein expression
[39]. In our current study of 26 nBAP1 negative UM,
20 (77%) harboured mutations in BAP1, which is
similar to the previous reports detailed above.
Of particular interest in our current study was the
identification of a subset of M3 UM (20/104; 19%)
that showed nBAP1 positivity, correlating with a sig-
nificantly increased survival time as compared with
the M3/nBAP1-negative UM (p5 0.014) (Figure 2B).
Whilst the follow-up is relatively short for these 20
individuals, the data support our previous description
of a patient with nBAP1 positive liver metastases
who was still alive after more than 10 years post
enucleation [51]. More recently, BAP1 IHC per-
formed at our centre showed nBAP1 positivity in
metastatic UM cells within the liver of a patient who
is alive 37 years after diagnosis of the primary UM.
This suggests that two distinct subgroups exist within
UM with loss of chromosome 3: those M3 UM with
a loss of BAP1 function, and those M3 UM with a
retained functional copy of BAP1. Indeed, three M3/
nBAP1 positive cases were analysed for BAP1 muta-
tions and found to be wild type. These data were
also reflected in the multivariate analysis where
nBAP1 was found to be the only independent vari-
able significantly associated with increased risk of
developing metastatic disease. Overall, our data
strongly suggest that bi-allelic inactivation of BAP1
is required to influence prognosis; on this basis, we
would predict that the loss of other genes on chromo-
some 3 may have little or no additional effect on
prognosis in this group.
In a small number of cases, however, BAP1 loss is
clearly not the metastatic driver. For example, 3/26
(12%) UM patients in our study who developed met-
astatic disease were found to have nBAP1 positive
primary tumours. Two of these patients also had
unfavourable clinical and histological characteristics,
which would have placed them in the ‘high risk’ cat-
egory for developing metastatic disease, irrespective
of the tumour’s nBAP1 status. These other factors
included epithelioid cell morphology, high mitotic
count, large tumour size, 8q gain, ciliary body
involvement, and extraocular growth [3].The remain-
ing case, however, is unusual in that it was D3 with
clinical and histological features of a low metastatic
risk tumour. Previous studies have suggested that D3
UM with a mutation in splicing Factor 3B Subunit
1A (SF3B1) have an increased risk of developing
metastases [52]. Further studies are necessary to
determine whether such a mutation is present in this
particular case.
Other unusual cases in our patient cohort included
three nBAP1 negative UM with no corresponding
loss of chromosome 3. Chromosome 3 copy number
for all three cases was re-examined by MSA, which
is able to detect isodisomy, i.e. loss of heterozygosity
due to acquisition of both copies of the chromosome
from the same parent. Only one of the three cases
showed isodisomy 3 by MSA. The remaining two
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cases were tested for BAP1 mutations, but were
found to be wild type, suggesting alternative mecha-
nisms of nBAP1 loss.
Cytoplasmic BAP1 expression findings
Our study is the first to characterize cBAP1 in UM
by IHC, and the first to investigate the link between
cBAP1 genotype and phenotype. Our observation of
‘focal perinuclear’ cBAP1 localisation is consistent
with a study by Gammon et al [43], who observed
‘clumped perinuclear’ cBAP1 in 53% of nBAP1 neg-
ative sporadic epithelioid Spitz tumours. They further
hypothesized that ‘focal perinuclear’ cBAP1 may be
trapped in the Golgi zone, which our experimental
findings using the cis Golgi marker, GM130, would
support. It should also be mentioned that mouse
acites Golgi reactive (MAG) antibodies have been
described in some monoclonal antibody preparations,
resulting in non-specific cross reactivity with blood
group A1 antigens present in patient tissues [53–55].
It is unlikely, given the prevalence of blood group
A1 in the population (35% individuals), however,
that MAG antibodies are responsible for the small
percentage of cases (11%) with ‘focal perinuclear’
positivity observed in our study. Moreover, a recent
study by Bononi et al also described cBAP1 localisa-
tion to the endoplasmic reticulum where it regulates
Ca21 release to promote apoptosis [56]. In fibroblasts
and mesothelial cells derived from individuals with a
heterozygous germline BAP11/– mutation, they dem-
onstrated a reduced Ca21 flux that reduced the ability
ofBAP11/– mutant cells to undergo apoptosis follow-
ing DNA damage. Taken together, these results sug-
gest that there is indeed a functional role of cBAP1
in particular cancer types requiring further study.
The preponderance of UM with ‘focal perinuclear’
cBAP1 that harbour truncating mutations is of inter-
est as one might assume that mutations causing pre-
mature stop codons would trigger nonsense-mediated
decay of the aberrant transcript, so that incorrect pro-
tein is not produced. One possibility, however, is that
the UM cells bypass the premature stop codon by
using alternative splice sites [57] and/or read-through
translation [58] to generate misfolded proteins that
are not able to exit the Golgi following processing.
Consistent with this, Jensen et al, who first described
BAP1, identified a number of putative N-linked
BAP1 glycosylation sites, suggesting that BAP1 may
traverse the Golgi during maturation [30]. Bhatta-
charya and colleagues [59] suggested an alternative
mechanism for the observation of ‘focal perinuclear’
cBAP1 in the form of cBAP1 aggregates promoted
by BAP1 mutations, which expose hydrophobic
regions of the protein, leading to beta amyloid aggre-
gation. However, their study proposed that specific
mis-sense mutations in the catalytic domain were
responsible for the observed aggregation, whereas
our sequencing results suggest that sporadic truncat-
ing mutations throughout BAP1 can induce the ‘focal
perinuclear’ phenotype. Further studies of the molec-
ular biology of the focal perinuclear phenotype will
be warranted.
Our results identifying six nBAP1 negative UM
with wild-type BAP1 is consistent with reports by
van de Nes et al [23] and Royer-Bertrand et al [12],
in which five and three cases, respectively, with this
phenotype/genotype were described. It is tempting to
speculate that a post-translational mechanism, perhaps
in the form of UBE2O upregulation, could be respon-
sible for the aberrant cytoplasmic localisation of
BAP1 in these cases. The putative E2/E3 hybrid ubiq-
uitin ligase, UBE2O, has been reported to mediate
cytoplasmic translocation of BAP1 by multi-
monoubiquitylation of the NLS. Auto-deubiquitylation
by BAP1 antagonizes the activity of UBE2O, promot-
ing its nuclear retention [44].
Finally, whilst our study found no link between
cBAP1 expression and overall survival (Log rank;
p5 0.33), it is of interest that Zhang et al [60] found
that high expression of cBAP1 in gliomas was signif-
icantly associated with worse overall survival com-
pared to low cBAP1 expression, although there was
no mention of any specific localisation of the cBAP1
in this study. A larger cohort of UM with a longer
follow-up period is required to ascertain whether a
dose-dependent effect of cBAP1 is of clinical
relevance.
In summary, we have demonstrated the importance
of nBAP1 protein expression as an independent
marker of prognosis in patients with UM and that
identifies a subpopulation of M3 tumours with
favourable survival times compared to their nBAP1-
negative counterparts. We also report that exclusion
of BAP1 protein from the nucleus is most commonly
associated with retention of cBAP1. The molecular
mechanisms underpinning ‘focal perinuclear’ cBAP1
remain unknown, and warrant further study.
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